The therapeutic inhibition of either pro-tumorigenic STAT3 or NF-κB signaling is currently being tested in clinical trials, for several cancer types including hepatocellular carcinoma (HCC), colorectal, prostate, breast cancer [156,214] and leukaemia [215,216]. The gene discussed is NFKB1; the disease is hepatocellular carcinoma.